cGAMP | 849214-04-6

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: cGAMP
• 英文别名: 2′,3′-cyclic GMP-AMP；3',3'-cGAMP；cyclic GMP-AMP；2’2’-cGAMP；3’,3’-cGAMP；2-amino-9-[(1S,6R,8R,9R,10S,15R,17R,18R)-17-(6-aminopurin-9-yl)-3,9,12,18-tetrahydroxy-3,12-dioxo-2,4,7,11,13,16-hexaoxa-3λ5,12λ5-diphosphatricyclo[13.3.0.06,10]octadecan-8-yl]-1H-purin-6-one
• CAS: 849214-04-6
• 化学式: C₂₀H₂₄N₁₀O₁₃P₂
• 分子量: 674.417
• InChiKey: RFCBNSCSPXMEBK-INFSMZHSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.9
• 重原子数：
  45
• 可旋转键数：
  2
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  325
• 氢给体数：
  7
• 氢受体数：
  18

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
  申请人：ADURO BIOTECH, INC.

  公开号：US10449211B2

  公开（公告）日：2019-10-22

  The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′-fluoro substituted, bis-3′,5′CDNs, and most preferably one or more 2′,2″-diF-Rp,Rp, bis-3′,5′CDNs.

  本发明提供了高活性环状二核苷酸（CDN）免疫刺激剂，它能通过最近发现的一种称为 STING（干扰素基因刺激器）的细胞质受体激活直流细胞、本发明的 CDN 以包含一种或多种环状嘌呤二核苷酸的组合物的形式提供，该组合物能诱导人类 STING 依赖性 I 型干扰素的产生、其中组合物中的环嘌呤二核苷酸是2′-氟取代的双-3′,5′CDN，最优选的是一种或多种2′,2″-diF-Rp,Rp,双-3′,5′CDN。
• Cyclic dinucleotides as anticancer agents
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10947263B2

  公开（公告）日：2021-03-16

  The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

  本发明涉及式（I）化合物（其中所有取代基均在此定义），以及包含本发明化合物的药学上可接受的组合物和使用所述组合物治疗各种疾病的方法。
• Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling
  申请人：CHINOOK THERAPEUTICS, INC.

  公开号：US11040053B2

  公开（公告）日：2021-06-22

  The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′-fluoro substituted, bis-3′,5′ CDNs, and most preferably one or more 2′,2″-diF-Rp,Rp, bis-3′,5′CDNs.

  本发明提供了高活性环状二核苷酸（CDN）免疫刺激剂，可通过最近发现的一种称为 STING（干扰素基因刺激器）的细胞质受体激活 DC。特别是，本发明的 CDN 以组合物的形式提供，该组合物包含一种或多种环状嘌呤二核苷酸，可诱导人类 STING 依赖性 I 型干扰素的产生、其中组合物中的环状嘌呤二核苷酸是 2′-氟取代的双-3′,5′CDN，最优选的是一种或多种 2′,2″-diF-Rp,Rp，双-3′,5′CDN。
• COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE" - DEPENDENT SIGNALLING
  申请人：ADURO BIOTECH, INC.

  公开号：US20180064745A1

  公开（公告）日：2018-03-08

  The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′-fluoro substituted, bis-3′,5′CDNs, and most preferably one or more 2′,2″-diF-Rp,Rp, bis-3′,5′CDNs.
• CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20200223883A1

  公开（公告）日：2020-07-16

  The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.